Globus Medical Inc

Globus Medical is a scaled musculoskeletal technology company, NOT a robotics pure-play. It sells spine/musculoskeletal implants and disposables (Musculoskeletal Solutions = 96.7% of Q2 2026 revenue) plus a capital-equipment enabling-tech layer (ExcelsiusGPS robotic navigation + Excelsius3D imaging + ExcelsiusFlex knee robot = 3.3% of revenue). Growth comes from implant share gains, not robot sales.

• monetization model: one-time hardware sales (spinal implants, trauma, biologics) + capital equipment (robotics/navigation/imaging) + recurring disposables/consumables/services; no subscription/SaaS disclosed. (GMED FY2023 10-K, Business; Accession 0001237831-24-000010; sec.gov )
• revenue mix: FY2023 segment note: Musculoskeletal Solutions ~$1,468M (~94% of net sales); Enabling Technologies ~$101M (~6%). (10-K, segment/revenue note)
• who pays: hospitals, ambulatory surgery centers, and health-system capital/supply-chain budgets; payers reimburse procedures, but providers write the purchase order. (10-K, Business/Customers)
• margin_value_capture: FY2023 gross margin ~68%; operating margin ~11% GAAP, pressured by NuVasive integration; value accrues in implant pull-through, robotic-capital installed base, and recurring disposables. (10-K, MD&A/Financials)

• customer classes: Health Systems & Providers (hospitals, ASCs, surgeons); payers reimburse but are not the direct economic buyer. (10-K, Business/Customers)

Globus Medical, Inc. is a medical device company focused on musculoskeletal implants and enabling technologies. Its common stock trades on the New York Stock Exchange under the ticker GMED.

The primary SEC registrant is:

• CIK: 0001490630
• EDGAR filing index:

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001490630&type=10-K&dateb=&owner=include&count=40

This EDGAR index is the primary source for GMED 10-K, 10-Q, and 8-K filings. The exact accession number of the most recent 10-K should be retrieved from this index and verified before any financial figure is used in a live research workflow.

The payer is generally the hospital, ambulatory surgery center, or healthcare system. The specifier is the surgeon. The economic buyer may be supply chain, value-analysis committees, or GPO/IDN contracting. The company recognizes revenue upon product shipment or surgery, depending on contractual terms and whether the sale is through direct sales reps or independent distributors.

From the company’s public SEC disclosures, the customer base can be described as:

• Hospitals and health systems: acute care facilities that perform spine surgery.
• Ambulatory surgery centers: increasingly important for outpatient spine procedures.
• Surgeons: the clinical specifiers who choose implant systems and technologies.
• Distributors and independent agents: used in some territories, especially international.
• GPOs and IDNs: contract vehicles that set pricing/access.

• Worldwide net sales $789.6M (+5.9% YoY; +5.6% constant currency)
• Musculoskeletal Solutions $763.5M (+7.5% YoY); Enabling Technologies $26.1M (−26% YoY, from $35.2M)
• H1 2026 net sales $1,549.5M (+15.3% YoY)
• GAAP net income $151.6M; GAAP diluted EPS $1.10 (−26% YoY, distorted by prior-year Nevro bargain purchase gain); Non-GAAP diluted EPS $1.34 (+55.8% YoY)
• Gross margin 69.4% (computed: $548.2M gross profit / $789.6M); GAAP operating margin 23.1%
• FY2026 guidance: revenue $3.18–3.22B (reaffirmed); non-GAAP EPS raised to $4.95–5.05 (from $4.70–4.80)

ExcelsiusGPS spine surgery robot + next-gen Excelsius3D; mid-cap profitable robotics pure-play in expanding spine surgery market (12.6% CAGR to $1.6B by 2035)

Q2 2026 earnings ~late Jul/early Aug; ExcelsiusGPS surpassed 115K robotic procedures; BMO initiated Outperform $94, RBC $115; international expansion at Apollo Hospitals India

1. Razor-and-blade ratio ≈ 1:29. Enabling Tech $26.1M : Musculoskeletal $763.5M (Q2 2026, 10-Q). The robotics layer is 3.3% of revenue and DECLINING −26% YoY while implants grow +7.5% — the pull-through is now driven by the installed base, not incremental robot sales. This falsifies the "robotics pure-play" framing; the robot is a land-and-expand tool, not the P&L.
2. Switching cost (surgeon/hospital): robot capital $0.5–1.5M + ~$150K/yr maintenance (pmarketresearch); single-site install = $1.3M (Southwoods Health, Feb 2026). Learning curve: sub-2% pedicle-screw breach rate requires ~58–64 cases per surgeon (pmarketresearch). Retraining + workflow disruption = multi-quarter switching friction that defends the installed base (~800 systems, ~80K cumulative procedures — roboticscenter.ai, Apr 2026; third-party est.).
3. Nevro bargain purchase (cost-of-moat vs moat-defended): acquired Nevro (SCS) April 2025 for $250M all-cash ($5.85/sh, 27% premium to 90-day VWAP) — ~0.62× EV on ~$405M FY2025 guided revenue. Generated a $110.5M bargain purchase gain (Q2 2025, 10-Q) = bought a distressed SCS leader (rechargeable SCS, painful diabetic neuropathy) below fair value. Defends entry into a ~$4.6B SCS market where Boston Scientific holds ~55% share (GlobalData) — a sub-scale "free option," not a moat on its own.